文献速递类风湿关节炎

托法替布治疗类风湿关节炎长达8.5年的长期安全性:全球临床试验整合分析

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
PubMed 文献 · Ann Rheum Dis · 2017-01-31

分析显示严重不良事件发生率为9.4/100患者年,严重感染为2.7/100患者年,带状疱疹为3.9/100患者年,恶性肿瘤(除外非黑色素瘤皮肤癌)为0.9/100患者年。按6个月间隔分析未发现严重感染、带状疱疹和恶性肿瘤发生率随暴露时间延长而显著增加,未观察到新的安全性信号。

要点

  • 托法替布治疗RA的严重感染发生率为2.7/100患者年,带状疱疹为3.9/100患者年。
  • 恶性肿瘤(除外NMSC)发生率为0.9/100患者年,NMSC为0.6/100患者年。
  • 按6个月间隔分析未发现严重感染、带状疱疹和恶性肿瘤发生率随暴露时间延长而增加。

核心结论

  • 托法替布治疗活动性RA长达8.5年的暴露分析显示不良事件发生率总体稳定,未观察到新的安全性信号。

主要发现

  • 严重不良事件发生率为9.4/100患者年(95%CI 9.0-9.9),严重感染为2.7/100患者年(95%CI 2.5-3.0)。
  • 全部带状疱疹发生率为3.9/100患者年(95%CI 3.6-4.2),播散性或多元带状疱疹为0.3/100患者年(95%CI 0.2-0.4)。
  • 机会性感染(除外结核)发生率为0.3/100患者年(95%CI 0.2-0.4),结核为0.2/100患者年(95%CI 0.1-0.3)。
  • 恶性肿瘤(除外非黑色素瘤皮肤癌)发生率为0.9/100患者年(95%CI 0.8-1.0),非黑色素瘤皮肤癌为0.6/100患者年(95%CI 0.5-0.7)。
  • 胃肠道穿孔发生率为0.1/100患者年(95%CI 0.1-0.2);按6个月间隔分析未发现严重感染、带状疱疹和恶性肿瘤发生率随暴露时间延长而显著增加。

临床怎么用

  • 长期使用托法替布治疗RA时,严重感染和带状疱疹仍是需要关注的不良事件,但发生率随暴露时间延长保持稳定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA. METHODS: Data were pooled for all tofacitinib-treated patients (data cut-off: 31 March 2015). Incidence rates (IRs; patients with event/100 patient-years) and 95% CIs are reported for adverse events (AEs) of interest. RESULTS: 6194 patients received tofacitinib for a total 19 406 patient-years' exposure; median exposure was 3.4 patient-years. IR (95% CI) for serious AEs was 9.4 (9.0 to 9.9); IR for serious infections was 2.7 (2.5 to 3.0). IR for (all) herpes zoster was 3.9 (3.6 to 4.2); IR for disseminated or multidermatomal herpes zoster was 0.3 (0.2 to 0.4). IR for opportunistic infections (excluding tuberculosis) was 0.3 (0.2 to 0.4) and was 0.2 (0.1 to 0.3) for tuberculosis. IR for malignancies (excluding non-melanoma skin cancer (NMSC)) was 0.9 (0.8 to 1.0); NMSC IR was 0.6 (0.5 to 0.7). IR for gastrointestinal perforations was 0.1 (0.1 to 0.2). Analysis of IR for serious infections, herpes zoster and malignancies by 6-month intervals did not reveal any notable increase in IR with longer-duration tofacitinib exposure. CONCLUSION: This analysis of tofacitinib exposure up to 8.5 years allowed estimation of safety events with improved precision versus previous tofacitinib reports. AEs were generally stable over time; no new safety signals were observed compared with previous tofacitinib reports. TRIAL REGISTRATION NUMBERS: NCT01262118, NCT01484561, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT00413699, NCT00661661; Results.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017. PMID: 28143815. doi:10.1136/annrheumdis-2016-210457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。